Edition:
United States

Fresenius SE & Co KGaA (FREG.DE)

FREG.DE on Xetra

73.46EUR
21 Jul 2017
Change (% chg)

€-1.37 (-1.83%)
Prev Close
€74.83
Open
€74.69
Day's High
€75.26
Day's Low
€73.29
Volume
1,786,269
Avg. Vol
980,497
52-wk High
€80.07
52-wk Low
€63.62

FREG.DE

Chart for FREG.DE

About

Fresenius SE & Co KGaA is a health care company. It operates in the healthcare sector and offers products and services for dialysis, hospitals and outpatient medical care. It focuses on the hospital operations and offers engineering and services for hospitals and other health care facilities. The Company’s operating segments... (more)

Overall

Beta: 0.59
Market Cap(Mil.): €40,718.56
Shares Outstanding(Mil.): 554.30
Dividend: 0.62
Yield (%): 0.84

Financials

  FREG.DE Industry Sector
P/E (TTM): 24.47 30.22 15.85
EPS (TTM): 3.00 -- --
ROI: 8.96 7.17 -8.31
ROE: 13.40 11.55 -7.95

Fresenius poaches Telefonica Deutschland CFO Rachel Empey

BERLIN, July 21 Fresenius named Rachel Empey as its chief financial officer on Friday, poaching her from Telefonica Deutschland.

Jul 21 2017

BRIEF-Fresenius SE says Akorn shareholders approved merger

* At yesterday's special meeting, shareholders of Akorn, Inc., have approved merger agreement with fresenius kabi, with 83.9 percent of outstanding shares being voted in favour of transaction. Source text for Eikon: Further company coverage:

Jul 20 2017

BRIEF-Akorn shareholders vote to approve merger agreement with Fresenius Kabi

* Akorn shareholders vote to approve merger agreement with Fresenius Kabi

Jul 19 2017

BRIEF-Fresenius says Fresenius Kabi expands production site in Portugal‍​

* ABOUT 80 NEW JOBS ARE BEING CREATED AT THE SANTIAGO DE BESTEIROS PLANT BY THE EXPANSION Source text: http://bit.ly/2tUfsVP Further company coverage: (Gdynia Newsroom)

Jul 06 2017

BRIEF-Stroeer says shareholder meeting agrees dividend increase

* following highly successful fiscal year 2016, the annual general meeting agrees to a substantial dividend increase to 1.10 euros.

Jun 14 2017

BRIEF-Cerus provides update on U.S. Platelet additive solution supply

* Cerus provides update on U.S. Platelet additive solution (pas) supply

Jun 07 2017

Exclusive: Mallinckrodt explores sale of generic drugs business - sources

Mallinckrodt Plc is exploring a sale of its generic drug unit, in a deal that could fetch as much as $2 billion and help pivot the specialty pharmaceutical maker toward higher-margin branded drugs, according to people familiar with the matter.

May 30 2017

BRIEF-Cerus provides U.S. business update

* A pending platelet additive solution shortage is expected to impact some U.S. blood centers producing intercept platelets

May 23 2017

REFILE-Fresenius vows to take breather after three deals

FRANKFURT, May 12 The head of German healthcare group Fresenius SE said he would abstain from the takeover market for now, after striking three deals worth billions of euros in total since taking over less than a year ago.

May 12 2017

Fresenius ups guidance on growth at generic drugs unit

FRANKFURT German healthcare group Fresenius on Wednesday toned up its earnings guidance for the year as demand for recently launched generic infusion drugs continued to grow at higher-than-expected rates.

May 03 2017

Earnings vs. Estimates